Enamel matrix proteins in the treatment of intrabony defects in patients with aggressive and chronic periodontitis: Randomized clinical trial

• Grant number: 15/19731-0
• Support Opportunities: Regular Research Grants
• Start date: February 01, 2016
• End date: July 31, 2018
• Field of knowledge: Health Sciences - Dentistry - Dental Clinics
• Principal Investigator: Antonio Wilson Sallum
• Grantee: Antonio Wilson Sallum
• Host Institution: Faculdade de Odontologia de Piracicaba (FOP). Universidade Estadual de Campinas (UNICAMP). Piracicaba , SP, Brazil
• Associated researchers: Enilson Antonio Sallum ; Márcio Zaffalon Casati ; Renato Corrêa Viana Casarin

Abstract

Approaches and objectives related to the treatment of patients with aggressive periodontitis are not markedly different compared patients with the chronic form. However, the large bone loss related to young age in this aggressive form, justify a well-founded strategy, intending to further stabilization of disease progression. For this, should make use of regenerative therapies in the advanced stages of treatment. Noteworthy is the use of proteins derived from the enamel matrix (EMD) in patients with chronic periodontitis, but there is little evidence about the effects of this material in aggressive periodontitis. Thus, the present study aims to evaluate the use of EMD in patients with aggressive periodontitis, comparing them to individuals with chronic periodontitis. Will then be selected 45 subjects, among patients with generalized chronic periodontitis (GCP) and generalized aggressive periodontitis (GAP), with one or more intra-bony defects in radiographic examination, with a minimum size of 4 mm deep and 2 mm horizontal, associated with a probing depth (PD) e6mm, to be treated according to the groups: GAP+OFD (n = 15) GAP patients which will receive open flap debridement; GAP+OFD/EMD (n=15) GAP patients which will receive open flap debridement and application of EMD; GCP+OFD/EMD (n=15) GCP patients which will receive open flap debridement and application of EMD. Clinical evaluations will be performed at baseline, 3, 6 months and 1 year after. At baseline, 7, 15, 45 days, 3, 6 months and 1 year after will be collect samples of gingival fluid to detect bone markers by Luminex / MAGpix technology. For the periods baseline, 3, 6 months and 1 year will be collected subgingival biofilm for the detection and quantification of periodontal pathogens by real-PCR. Will still be carried x-rays on baseline, 6 months and 1 year after, and questionnaires about patient satisfaction and perception of therapy at baseline, 7 days and 6 months. To compare the parameters evaluated, ANOVA, Tukey, chi-square, Spearman and Person tests will be used (± = 5%). (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

FILETO MAZZONETTO, ANA LIVIA; CASARIN, RENATO CORREA VIANA; SANTAMARIA, MAURO PEDRINE; ANDERE, NAIRA MARIA REBELATTO BECHARA; ARAUJO, CASSIA FERNANDES; VIDEIRA CLIMA DA SILVA, RAFAELA; PURISACA, JAVIER EDUARDO VIVANCO; SALLUM, ENILSON ANTONIO; SALLUM, ANTONIO WILSON. Clinical, radiographic and patient-centered outcomes after use of enamel matrix proteins for the treatment of intrabony defects in patients with aggressive periodontitis: A 12-month multicenter clinical trial. Journal of Periodontology, NOV 2020. (15/19731-0)

FILETO MAZZONETTO, ANA LIVIA; CASARIN, RENATO CORREA VIANA; SANTAMARIA, MAURO PEDRINE; ANDERE, NAIRA MARIA REBELATTO BECHARA; ARAUJO, CASSIA FERNANDES; VIDEIRA CLIMA DA SILVA, RAFAELA; PURISACA, JAVIER EDUARDO VIVANCO; SALLUM, ENILSON ANTONIO; SALLUM, ANTONIO WILSON. Clinical, radiographic and patient-centered outcomes after use of enamel matrix proteins for the treatment of intrabony defects in patients with aggressive periodontitis: A 12-month multicenter clinical trial. Journal of Periodontology, v. 92, n. 7, p. 995-1006, JUL 2021. (15/19731-0)